OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

기사 요약

OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.